Saturday , May 21 2022

FLU or COVID-19? What are the main differences ©


Influenza and COVID-19 are infectious diseases caused by different viruses:

  • COVID-19 is infected with the corona virus SARS-CoV-2.
  • Influenza is caused by an influenza virus.

Some of the symptoms of influenza and COVID-19 are similar. For this reason, it is difficult to differentiate between them on the basis of symptoms alone, and testing is needed to confirm the diagnosis.
There is still much unknown about COVID-19 and the virus that causes it.
From the information available so far, Kovid-19 seems to spread more easily than influenza and cause more serious problems in some people. In the case of COVID-19, the longer it takes for symptoms to appear, the longer people can be contagious.

Signs and Symptoms

COVID-19 and influenza have many symptoms, mild or severe, and life-threatening complications.

The most common symptoms of COVID-19 and influenza are:

  • Fever or fever / cold
  • Cough
  • Difficulty breathing
  • Fatigue • Sore throat
  • Coryza or stuffy nose
  • Muscle aches or body aches
  • Headache



Influenza viruses can cause severe forms of the disease with the above symptoms.


People with COVID-19 have a wide range of reported symptoms – from mild to severe.

Other signs and symptoms of COVID-19 other than influenza: anorexia, nausea, vomiting, diarrhea, weak mental state, anosmia (loss of smell) or agusia (loss of taste) for no apparent reason.

How long do symptoms last after exposure and infection?

Symptoms of COVID-19 and influenza may appear one day after exposure to the virus.



Usually, influenza appears suddenly: 1 to 4 days after infection.


In COVID-19, symptoms may appear 2-14 days after exposure to the virus – on average 5-7 days.

How long can a person spread the virus?

In COVID-19 and influenza, the virus is spread at least one day before the onset of symptoms.


If a person has COVID-19, it can be contagious for longer than they have a fever.


The first 3-4 days of illness are most contagious in older children and adults, but many remain contagious for up to 7 days.
Infants and people with weakened immune systems are more likely to be infected.


How long the virus that causes COVID-19 can spread is still under investigation.

People are more likely to catch the virus 2 days before the onset of symptoms and to remain contagious for at least 10 days after the onset of symptoms or symptoms. If someone has any of the symptoms or their symptoms disappear, they will remain contagious for at least 10 days after being tested positive for COVID-19.

How it spreads COVID-19 and influenza can be transmitted from person to person through close contact:

  • Respiratory tract infections caused by droplets produced by an infected person when they sneeze or cough
  • By having close contact with an infected person (touch, handshake)
  • By touching dirty surfaces, dirty hands can get into the mouth, nose, or eyes.

Differences In some populations and age groups, Kovid-19 is more contagious than influenza.

The virus that causes COVID-19 spreads rapidly and easily to many people and continues to spread among people over time.

People at high risk for serious illness.

COVID-19 and influenza can cause serious illness and complications.

Most vulnerable people:

Most people infected with leptospirosis are contagious the day before they show symptoms.

  • The elderly
  • People with certain comorbidities
  • Pregnant women


Healthy children are more likely to have complications than COVID-19.
Infants and children with basic medical conditions are at higher risk for influenza and COVID-19.


Infants are at higher risk of developing serious illnesses caused by influenza.


School-aged children with COVID-19 are more likely to develop multicellular inflammatory syndrome (MIS-C), which is a rare but serious complication of COVID-19.


COVID-19 and influenza can lead to complications including:

  • Pneumonia
  • Respiratory failure
  • Acute Respiratory Distress Syndrome (i.e. fluid in the lungs)
  • Septicemia
  • Heart attack (e.g. heart attack, heart attack)
  • Multiple organ failure (respiratory failure, renal failure, shock)
  • Exacerbation of chronic medical conditions (including lung, heart, nervous system or diabetes)
  • Inflammation of the heart, brain or muscle tissue
  • Secondary bacterial infections (i.e., infections that already occur in people infected with influenza or COVID-19)



Recovery from influenza can take anywhere from a few days to a maximum of two weeks. Some people may develop the complications listed above.


Further complications associated with COVID-19 may include:

  • Blood clots in the veins and arteries of the lungs, heart, feet or brain
  • Multisystem inflammatory syndrome in children (MIS-C)

Recovery from COVID-19 may take 2-4 weeks.

Approved treatments

People who are at high risk for complications or who have been hospitalized for COVID-19 or influenza should receive supportive care to avoid symptoms and complications.



Influenza can be treated with prescription antiviral drugs.


The protocol for Kovid-19 infection has been revised following the recommendation of the Infectious Diseases Commission of the Ministry of Health, with the support of the Kovid-19 Scientific Commission of the Ministry.

Basic Recommendations:

  • A person with asymptomatic SARS-CoV-2 infection does not need drug treatment.
  • Patient monitoring is very important, as is the severity of the suffering requiring changes in treatment attitudes related to the different treatment classes used.
  • Maintaining the diverse / complex manifestations of COVID-19 requires collaboration between physicians from different medical specialties.
  • Antivirals are more effective because they are given earlier in the course of the disease, preferably in the first 7-10 days; This is why antivirals are primarily recommended for mild to moderate forms of the disease.
  • Among the useful antivirals, Remedivir is recommended only in forms of moderate or high severity (severe / critical forms), depending on the criteria of availability, efficacy and risk.

These recommendations are periodically reviewed in the light of generally accepted scientific information from medical forums.



Vaccine developers and other researchers and manufacturers are currently accelerating the development of a vaccine to prevent COVID-19. Any vaccine entering the EU market must meet all scientific standards for safety, efficacy, and quality before it can be purchased and used. If severe side effects are found, the vaccine is not available for use in the European Union.


There are several flu vaccines produced each year to protect against 3 or 4 types of influenza viruses, which are expected to spread each year.

Influenza vaccination is the most effective preventive measure against seasonal influenza.

Vaccination should be done every year from mid-autumn. The flu season lasts from October to May, depending on the virus that spreads each year.

On December 3, in the anti-influenza immunization program for the 2020-2021 season, the Nimi Public Health Directorate received the new 12 percent vaccine for influenza – 12,800 doses of vaccine grip tetra.

During the epidemic season 2020-2021, 101,241 doses of influenza vaccine were requested, of which 80,070 doses were received. In stock, there are 40,078 doses of Family Doctors and DSP Neema.

39,992 doses were given. No adverse reactions were reported following immunizations.



Source link